Symbols / SCNI
SCNI Chart
About
Scinai Immunotherapeutics Ltd., a biopharmaceutical company, focuses on developing, manufacturing, and commercializing inflammation and immunology biological products for the treatment of infectious and autoimmune diseases in Israel. It develops nanosized VHH antibodies (nanoAbs) targeting diseases with unmet medical needs; and PC111, a monoclonal antibody for treating pemphigus, steven johnson's syndrome, and toxic epidermal necrolysis. The company also provides contract development and manufacturing organization services to biotech companies. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Gottingen for the development and commercialization of COVID-19 nanosized antibody. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 2.81M |
| Enterprise Value | 5.21B | Income | 347.00K | Sales | 1.15M |
| Book/sh | 1.47 | Cash/sh | 989000.00 | Dividend Yield | — |
| Payout | 0.00% | Employees | 31 | IPO | — |
| P/E | 0.22 | Forward P/E | — | PEG | — |
| P/S | 2.45 | P/B | 0.60 | P/C | — |
| EV/EBITDA | -772.37 | EV/Sales | 4541.97 | Quick Ratio | 0.53 |
| Current Ratio | 0.71 | Debt/Eq | 29.98 | LT Debt/Eq | — |
| EPS (ttm) | 4.00 | EPS next Y | — | EPS Growth | — |
| Revenue Growth | 36.10% | Earnings | 2024-05-15 16:00 | ROA | -39.55% |
| ROE | 17.92% | ROIC | — | Gross Margin | -146.99% |
| Oper. Margin | -4.87% | Profit Margin | 4.48% | Shs Outstand | 3.19M |
| Shs Float | 5.35B | Short Float | 1.51% | Short Ratio | 0.92 |
| Short Interest | — | 52W High | 6.18 | 52W Low | 0.61 |
| Beta | 1.89 | Avg Volume | 48.94K | Volume | 41.15K |
| Target Price | — | Recom | None | Prev Close | $0.86 |
| Price | $0.88 | Change | 2.44% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.84
Latest analyst target
3. DCF / Fair value
$-19.13
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.84
Low
—
High
—
Mean
—
- Israel backs robot-run sterile drug line with NIS 5M Scinai grant - Stock Titan Wed, 25 Feb 2026 13
- Scinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with Recipharm - PR Newswire ue, 17 Feb 2026 12
- Market Recap: Is IOTR stock heavily shorted - 2025 Risk Factors & Real-Time Volume Spike Alerts - baoquankhu1.vn Wed, 25 Feb 2026 05
- Scinai Immunotherapeutics Buys Recipharm Israel Unit, Seals Strategic CDMO Pact - TipRanks ue, 17 Feb 2026 14
- What’s the fair value of QuinStreet Inc. stock - CEO Change & Comprehensive Market Scan Insights - mfd.ru ue, 24 Feb 2026 22
- Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l. - PR Newswire hu, 05 Jun 2025 07
- There Are Some Reasons To Suggest That Scinai Immunotherapeutics' (NASDAQ:SCNI) Earnings Are A Poor Reflection Of Profitability - Yahoo Finance Fri, 29 Nov 2024 08
- SCNI Stock Touches 52-Week Low at $2.18 Amid Market Challenges - Investing.com UK Wed, 09 Apr 2025 07
- Geopolitics Watch: Will Inhibrx Biosciences Inc stock recover after earnings - Weekly Investment Summary & Long-Term Safe Investment Ideas - baoquankhu1.vn Fri, 13 Feb 2026 13
- Can NOEMR stock double in the next year - Global Markets & Intraday High Probability Alerts - mfd.ru Fri, 20 Feb 2026 21
- PLUG Stock Alert: Plug Power Gets Approval for HyVia Acquisition - InvestorPlace Mon, 15 Jul 2024 07
- SCNI - Scinai Immunotherapeutics Ltd. Latest Stock News & Market Updates - Stock Titan Mon, 11 Sep 2023 11
- Why Is Kaival Brands Innovations (KAVL) Stock Down 33% Today? - InvestorPlace Mon, 17 Jun 2024 07
- How geopolitical tensions affect Earlyworks Co. Ltd Depositary Receipt stock - Weekly Gains Summary & Real-Time Volume Surge Alerts - mfd.ru ue, 17 Feb 2026 17
- Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet - PR Newswire ue, 02 Sep 2025 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 3.40M | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.23 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -6.90M | -5.28M | -7.47M | -9.90M |
| TotalUnusualItems | 14.77M | 3.09M | 2.23M | -487.00K |
| TotalUnusualItemsExcludingGoodwill | 14.77M | 3.09M | 2.23M | -487.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | 4.80M | -6.50M | -5.80M | -8.21M |
| ReconciledDepreciation | 1.65M | 514.00K | 562.00K | 471.00K |
| ReconciledCostOfRevenue | 1.24M | 0.00 | 0.00 | |
| EBITDA | 7.87M | -2.19M | -5.23M | -10.39M |
| EBIT | 6.22M | -2.70M | -5.80M | -10.86M |
| NetInterestIncome | -1.33M | 115.00K | 3.03M | 3.14M |
| InterestExpense | 1.42M | 3.80M | 0.00 | 3.49M |
| InterestIncome | 100.00K | 3.92M | 3.05M | 3.15M |
| NormalizedIncome | -6.57M | -9.59M | -8.03M | -7.72M |
| NetIncomeFromContinuingAndDiscontinuedOperation | 4.80M | -6.50M | -5.80M | -8.21M |
| TotalExpenses | 9.30M | 9.71M | 11.06M | 10.86M |
| RentExpenseSupplemental | 101.05K | |||
| TotalOperatingIncomeAsReported | -8.64M | -9.71M | -11.06M | -10.86M |
| DilutedAverageShares | 806.37K | 390.66K | 188.52K | 141.14K |
| BasicAverageShares | 806.37K | 390.66K | 188.52K | 141.14K |
| DilutedEPS | 0.00 | -16.00 | -40.00 | -80.00 |
| BasicEPS | 0.00 | -16.00 | -40.00 | -80.00 |
| DilutedNIAvailtoComStockholders | 0.00 | -6.50M | -5.80M | -8.21M |
| NetIncomeCommonStockholders | 0.00 | -6.50M | -5.80M | -8.21M |
| PreferredStockDividends | 4.80M | |||
| NetIncome | 4.80M | -6.50M | -5.80M | -8.21M |
| NetIncomeIncludingNoncontrollingInterests | 4.80M | -6.50M | -5.80M | -8.21M |
| NetIncomeContinuousOperations | 4.80M | -6.50M | -5.80M | -8.21M |
| PretaxIncome | 4.80M | -6.50M | -5.80M | -8.21M |
| OtherIncomeExpense | 14.77M | 3.09M | 2.23M | -487.00K |
| SpecialIncomeCharges | 14.76M | 0.00 | 0.00 | |
| OtherSpecialCharges | -14.76M | |||
| GainOnSaleOfSecurity | 7.00K | 3.09M | 2.23M | -487.00K |
| NetNonOperatingInterestIncomeExpense | -1.33M | 115.00K | 3.03M | 3.14M |
| TotalOtherFinanceCost | 10.00K | 8.00K | 21.00K | 9.00K |
| InterestExpenseNonOperating | 1.42M | 3.80M | 0.00 | 3.49M |
| InterestIncomeNonOperating | 100.00K | 3.92M | 3.05M | 3.15M |
| OperatingIncome | -8.64M | -9.71M | -11.06M | -10.86M |
| OperatingExpense | 8.06M | 9.71M | 11.06M | 10.86M |
| OtherOperatingExpenses | -9.00K | -12.00K | ||
| DepreciationAmortizationDepletionIncomeStatement | 176.68K | |||
| DepreciationAndAmortizationInIncomeStatement | 176.68K | |||
| DepreciationIncomeStatement | 176.68K | |||
| ResearchAndDevelopment | 5.53M | 5.21M | 5.76M | 3.25M |
| SellingGeneralAndAdministration | 2.53M | 4.50M | 5.30M | 7.62M |
| GeneralAndAdministrativeExpense | 7.72M | |||
| OtherGandA | 2.71M | |||
| RentAndLandingFees | 101.05K | |||
| SalariesAndWages | 4.90M | |||
| GrossProfit | -580.00K | 0.00 | 0.00 | |
| CostOfRevenue | 1.24M | 0.00 | 0.00 | |
| TotalRevenue | 658.00K | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 658.00K | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 3.41B | 1.86B | 989.29M | 739.05M |
| ShareIssued | 3.41B | 1.86B | 989.29M | 739.05M |
| NetDebt | 14.50M | 6.01M | 9.79M | |
| TotalDebt | 2.09M | 20.56M | 21.54M | 28.98M |
| TangibleBookValue | 4.35M | -4.57M | -1.76M | 982.00K |
| InvestedCapital | 4.61M | 14.80M | 18.32M | 28.15M |
| WorkingCapital | 585.00K | 3.67M | 12.03M | 15.40M |
| NetTangibleAssets | 9.98M | -4.57M | -1.76M | 982.00K |
| CapitalLeaseObligations | 1.83M | 1.19M | 1.46M | 1.82M |
| CommonStockEquity | 4.35M | -4.57M | -1.76M | 982.00K |
| PreferredStockEquity | 5.63M | |||
| TotalCapitalization | 10.24M | 14.80M | 18.32M | 28.15M |
| TotalEquityGrossMinorityInterest | 9.98M | -4.57M | -1.76M | 982.00K |
| StockholdersEquity | 9.98M | -4.57M | -1.76M | 982.00K |
| GainsLossesNotAffectingRetainedEarnings | -1.74M | -1.74M | -2.01M | -2.06M |
| OtherEquityAdjustments | -1.74M | -1.74M | -2.01M | -2.06M |
| RetainedEarnings | -117.54M | -122.33M | -115.83M | -110.04M |
| AdditionalPaidInCapital | 123.63M | 119.51M | 116.08M | 113.08M |
| CapitalStock | 5.63M | 0.00 | 0.00 | 0.00 |
| CommonStock | 0.00 | 0.00 | 0.00 | 0.00 |
| PreferredStock | 5.63M | 0.00 | ||
| TotalLiabilitiesNetMinorityInterest | 3.47M | 22.04M | 28.83M | 31.05M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 1.67M | 20.26M | 26.49M | 28.61M |
| DerivativeProductLiabilities | 3.00K | 96.00K | 5.33M | 0.00 |
| EmployeeBenefits | 95.00K | |||
| NonCurrentPensionAndOtherPostretirementBenefitPlans | 95.00K | |||
| TradeandOtherPayablesNonCurrent | 0.00 | |||
| LongTermDebtAndCapitalLeaseObligation | 1.66M | 20.16M | 21.16M | 28.61M |
| LongTermCapitalLeaseObligation | 1.40M | 797.00K | 1.08M | 1.45M |
| LongTermDebt | 260.00K | 19.37M | 20.08M | 27.16M |
| CurrentLiabilities | 1.81M | 1.78M | 2.34M | 2.44M |
| CurrentDeferredLiabilities | 225.00K | 0.00 | ||
| CurrentDeferredRevenue | 225.00K | 0.00 | ||
| CurrentDebtAndCapitalLeaseObligation | 424.00K | 396.00K | 382.00K | 375.00K |
| CurrentCapitalLeaseObligation | 424.00K | 396.00K | 382.00K | 375.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 484.00K | 709.00K | ||
| PayablesAndAccruedExpenses | 1.16M | 1.38M | 1.96M | 2.07M |
| CurrentAccruedExpenses | 781.00K | 849.00K | 1.24M | 1.07M |
| Payables | 376.00K | 535.00K | 716.00K | 999.00K |
| AccountsPayable | 376.00K | 535.00K | 716.00K | 999.00K |
| TotalAssets | 13.45M | 17.47M | 27.07M | 32.04M |
| TotalNonCurrentAssets | 11.06M | 12.03M | 12.70M | 14.19M |
| OtherNonCurrentAssets | 444.00K | |||
| NetPPE | 11.06M | 12.03M | 12.70M | 14.19M |
| AccumulatedDepreciation | -4.46M | -2.81M | -2.42M | -2.13M |
| GrossPPE | 15.51M | 14.83M | 15.12M | 16.32M |
| Leases | 3.72M | 3.72M | 3.92M | 4.43M |
| ConstructionInProgress | 0.00 | 7.45M | 7.83M | 8.86M |
| OtherProperties | 4.02M | 3.34M | 3.04M | 2.69M |
| MachineryFurnitureEquipment | 7.77M | 321.00K | 332.00K | 339.00K |
| BuildingsAndImprovements | 7.83M | |||
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 2.39M | 5.45M | 14.37M | 17.84M |
| RestrictedCash | 131.00K | 140.00K | 140.00K | 143.00K |
| PrepaidAssets | 79.00K | 71.00K | 45.00K | 228.00K |
| Receivables | 217.00K | 366.00K | 110.00K | 98.00K |
| OtherReceivables | 134.00K | 366.00K | 110.00K | 98.00K |
| AccountsReceivable | 83.00K | 0.00 | ||
| CashCashEquivalentsAndShortTermInvestments | 1.96M | 4.87M | 14.07M | 17.37M |
| CashAndCashEquivalents | 1.96M | 4.87M | 14.07M | 17.37M |
| CashFinancial | 54.04M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -6.35M | -10.02M | -8.10M | -7.57M |
| RepaymentOfDebt | -392.62K | |||
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 2.00M | 139.00K | 932.00K | 21.43M |
| CapitalExpenditure | -12.00K | -637.00K | -836.00K | -139.00K |
| InterestPaidSupplementalData | 143.00K | 833.00K | 916.00K | 0.00 |
| EndCashPosition | 2.10M | 5.01M | 14.21M | 17.52M |
| BeginningCashPosition | 5.01M | 14.21M | 17.52M | 3.08M |
| EffectOfExchangeRateChanges | -9.00K | -272.00K | -1.98M | 575.00K |
| ChangesInCash | -2.91M | -8.93M | -1.32M | 13.87M |
| FinancingCashFlow | 3.44M | 1.09M | 6.78M | 21.43M |
| CashFlowFromContinuingFinancingActivities | 3.44M | 1.09M | 6.78M | 21.43M |
| ProceedsFromStockOptionExercised | 1.44M | 947.00K | 5.84M | 0.00 |
| NetCommonStockIssuance | 2.00M | 139.00K | 932.00K | 21.43M |
| CommonStockIssuance | 2.00M | 139.00K | 932.00K | 21.43M |
| NetIssuancePaymentsOfDebt | -392.62K | |||
| NetLongTermDebtIssuance | -392.62K | |||
| LongTermDebtPayments | -392.62K | |||
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | -12.00K | -637.00K | -836.00K | -139.00K |
| CashFlowFromContinuingInvestingActivities | -12.00K | -637.00K | -836.00K | -139.00K |
| NetOtherInvestingChanges | 9.33K | |||
| NetPPEPurchaseAndSale | -12.00K | -637.00K | -836.00K | -139.00K |
| SaleOfPPE | 12.87K | |||
| PurchaseOfPPE | -12.00K | -637.00K | -836.00K | -139.00K |
| OperatingCashFlow | -6.33M | -9.38M | -7.26M | -7.43M |
| CashFlowFromContinuingOperatingActivities | -6.33M | -9.38M | -7.26M | -7.43M |
| InterestReceivedCFO | 0.00 | |||
| InterestPaidCFO | -10.62K | |||
| ChangeInWorkingCapital | 112.00K | -796.00K | 271.00K | 704.00K |
| ChangeInOtherCurrentLiabilities | -314.00K | -58.00K | -156.00K | -150.00K |
| ChangeInOtherCurrentAssets | 284.00K | 43.00K | 153.00K | 148.00K |
| ChangeInPayablesAndAccruedExpense | 1.00K | -491.00K | 134.00K | 647.00K |
| ChangeInPayable | 1.00K | -491.00K | 134.00K | 647.00K |
| ChangeInAccountPayable | -156.00K | -150.00K | -175.00K | 3.00K |
| ChangeInReceivables | 141.00K | -290.00K | 140.00K | 59.00K |
| ChangesInAccountReceivables | -83.00K | |||
| OtherNonCashItems | -13.48M | 401.00K | -3.90M | -3.15M |
| StockBasedCompensation | 682.00K | 1.14M | 1.60M | 2.76M |
| DepreciationAmortizationDepletion | 1.65M | 514.00K | 562.00K | 471.00K |
| DepreciationAndAmortization | 1.65M | 514.00K | 562.00K | 471.00K |
| Depreciation | 1.65M | 514.00K | 562.00K | 471.00K |
| OperatingGainsLosses | -93.00K | -4.14M | ||
| PensionAndEmployeeBenefitExpense | 0.00 | |||
| GainLossOnInvestmentSecurities | -93.00K | -4.14M | ||
| NetIncomeFromContinuingOperations | 4.80M | -6.50M | -5.80M | -8.21M |
Public Trades for SCNI
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|